B

BrainChild Bio

CAR T therapies targeting CNS tumors

Research Associate - Process Development

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeSeattle, WA, USA$90k - $105k /yrHybrid

About the Job

Requirements

  • A bachelor's degree in Bioengineering, Chemical Engineering, Biology, or another related discipline is required.
  • At least 2 years of relevant laboratory experience is required.
  • Proficiency with mammalian cell culture sterile technique is required.
  • Proficiency with an electronic laboratory notebook and report writing is required.
  • Flexibility to work occasional weekends is required.

Responsibilities

  • Design and execute experiments supporting cell therapy process development, including Design of Experiments studies to efficiently optimize unit operations.
  • Support planning before study execution, including batch record authoring and reagent and material preparation.
  • Support troubleshooting during study execution and evaluation of potential impacts.
  • Document experiments thoroughly and promptly using electronic laboratory notebooks.
  • Perform statistical data analysis using JMP software.
  • Author study reports detailing experimental work and summarizing results.
  • Present experimental findings to cross-functional teams after study completion.

Desired Qualifications

  • Prior experience in the cell therapy industry is preferred.

About the Company

BrainChild Bio

CAR T therapies targeting CNS tumors

What BrainChild Bio does: It develops CAR T cell therapies to treat tumors in the central nervous system, focusing on children first and then expanding to adults with glioblastoma. How its product works: The lead therapy, BCB-276, uses a patient’s own T cells engineered to target B7-H3, and is given directly into the cerebrospinal fluid to reach brain and spine tumors. The company is also advancing a triple-targeting candidate, BCB-214, toward initial glioblastoma testing. How it differs from competitors: BrainChild Bio relies on autologous CAR T cells delivered locoregionally into CSF, with technology licensed from Seattle Children’s and strong ties to that institution, aiming at pediatric DIPG and other CNS cancers. What its goal is: To complete the Phase 2 ILLUMINATE trial to support a future regulatory filing for BCB-276 and to broaden its pipeline for CNS tumors, including early work on glioblastoma, supported by a recent $116 million Series A.

Company size
51-200
Company stage
Series A
Total funding
$116M
Headquarters
Seattle, WA
Founded
Not listed

Recently Posted Jobs

Explore more opportunities at BrainChild Bio

See more jobs